Chester County News and Community Website
MALVERN, PA — Ocugen Inc. (NASDAQ: OCGN) this week announced positive results from the Phase 2/3, observer-blind, immuno-bridging and broadening study of its COVID-19 vaccine candidate, COVAXIN™ (BBV152; Clinicaltrials.gov, NCT05258669), …
Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN (BBV152) Read More
PLYMOUTH MEETING, PA — New research published in the October 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms the safety of mRNA vaccines in people with cancer undergoing immunotherapy treatment. The researchers …
Study: Cancer Patients Treated with Immunotherapy Can Safely Receive mRNA COVID-19 Vaccines Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that the company recently entered into an exclusive license agreement with Washington University in St. Louis, MO for the rights to develop, …
Ocugen Announces Agreement With Washington University for Commercialization of Intranasal COVID-19 Vaccine Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration recently issued an emergency use authorization (EUA) for the Novavax COVID-19 Vaccine, Adjuvanted for the prevention of COVID-19 caused by severe …
FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine, Adjuvanted Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced the recent publication of positive pediatric Phase 2/3 study results in children aged 2–18 years for the COVID-19 vaccine COVAXIN™ (BBV152) in …
Ocugen Announces Publication of Positive Results of COVID-19 Vaccine Trial for Children 2-18 Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that the U.S. Food and Drug Administration (FDA) recently lifted its clinical hold on the Company’s Investigational New Drug application (IND) to …
Ocugen, Inc. Announces FDA Lifts Clinical Hold for Its COVID-19 Vaccine Candidate Read More
MALVERN, PA — More than one year after the first COVID-19 vaccination was administered in the United States and more than 545 million doses later, new data from a survey …
Ocugen/Harris Poll Finds Americans Want More COVID-19 Vaccine Options Read More
RADNOR, PA — NRx Pharmaceuticals (NASDAQ: NRXP) states it has received scientific evidence from the Israel Institute for Biological Research (IIBR) that the BriLife® vaccine may produce effective levels of …
NRx Announces Publication of Initial Findings of BriLife Vaccine-produced Antibodies Against Omicron Variant Read More
WASHINGTON, D.C. — On Friday, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) for the Moderna COVID-19 Vaccine to shorten the time between the completion of …
FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine to Five Months Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration announced that this week it has amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine to:
FDA Takes Multiple Actions to Expand Use of Pfizer-BioNTech COVID-19 Vaccine Read More